Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
暂无分享,去创建一个
M. Garnett | A. Bardelli | C. Isella | L. Trusolino | A. Bertotti | E. Medico | E. Zanella | F. Di Nicolantonio | M. Linnebacher | A. Sartore-Bianchi | S. Siena | G. Picco | M. Montone | A. Cassingena | Fabiane Barbosa | G. Corti | S. Arena | Pamela Arcella | L. Lazzari | Carlotta Cancelliere | L. Novara | E. Durinikova | F. Barbosa | Luca Novara
[1] A. Bardelli,et al. Evolving neoantigen profiles in colorectal cancers with DNA repair defects , 2019, Genome Medicine.
[2] A. Bardelli,et al. A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. , 2019, Clinical colorectal cancer.
[3] Emanuel J. V. Gonçalves,et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens , 2019, Nature.
[4] L. Kategaya,et al. Werner Syndrome Helicase Is Required for the Survival of Cancer Cells with Microsatellite Instability , 2019, iScience.
[5] Jesse J. Lipp,et al. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells , 2019, bioRxiv.
[6] Joshua M. Korn,et al. Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.
[7] James M. McFarland,et al. WRN Helicase is a Synthetic Lethal Target in Microsatellite Unstable Cancers , 2019, Nature.
[8] Hans Clevers,et al. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. , 2018, Cell stem cell.
[9] Kyoung-Mee Kim,et al. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy , 2018, Nature Genetics.
[10] Joshua M. Dempster,et al. Genetic and transcriptional evolution alters cancer cell line drug response , 2018, Nature.
[11] A. Bardelli,et al. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. , 2018, Cancer cell.
[12] Robert E Denroche,et al. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. , 2018, Cancer discovery.
[13] Cyriac Kandoth,et al. Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer , 2018, Cell.
[14] Andrea Sottoriva,et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers , 2018, Science.
[15] R. Lothe,et al. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies , 2017, Clinical Cancer Research.
[16] Claudio Isella,et al. A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem–Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy , 2017, Clinical Cancer Research.
[17] C. Swanton,et al. Tumor Evolution as a Therapeutic Target. , 2017, Cancer discovery.
[18] Rameen Beroukhim,et al. Patient-derived xenografts undergo murine-specific tumor evolution , 2017, Nature Genetics.
[19] Elisa Ficarra,et al. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer , 2017, Nature Communications.
[20] Davide Prandi,et al. Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. , 2017, Cancer discovery.
[21] Hans Clevers,et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts , 2017, Nature Reviews Cancer.
[22] Henrik Edgren,et al. Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response , 2017, Breast cancer.
[23] Agnieszka K Witkiewicz,et al. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility , 2017, Gut.
[24] John W. Cassidy,et al. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds , 2016, Cell.
[25] V. Torri,et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[26] J. Swensen,et al. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine , 2016, Familial Cancer.
[27] A. Bardelli,et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations , 2016, Science Translational Medicine.
[28] Mari Mino-Kenudson,et al. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. , 2016, Cancer discovery.
[29] R. Bosotti,et al. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer , 2015, Journal of the National Cancer Institute.
[30] Gang Li,et al. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. , 2015, Cancer discovery.
[31] David E. Fisher,et al. Precision medicine for cancer with next-generation functional diagnostics , 2015, Nature Reviews Cancer.
[32] Joshua A. Bittker,et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.
[33] R. Scharpf,et al. The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer , 2015, Nature.
[34] Jeffrey S. Morris,et al. The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.
[35] V. Torri,et al. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas , 2015, Clinical Cancer Research.
[36] Ron Bose,et al. HER2 activating mutations are targets for colorectal cancer treatment. , 2015, Cancer discovery.
[37] Beatriz Bellosillo,et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.
[38] Marco Beccuti,et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets , 2015, Nature Communications.
[39] M. J. van de Vijver,et al. Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract , 2015, Journal of Translational Medicine.
[40] G. Inghirami,et al. Stromal contribution to the colorectal cancer transcriptome , 2015, Nature Genetics.
[41] Sabine Tejpar,et al. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies , 2015, Science Translational Medicine.
[42] M. Salido,et al. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer , 2015, Clinical Cancer Research.
[43] A. Bardelli,et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. , 2014, Cancer discovery.
[44] Kristian Cibulskis,et al. RNF43 is frequently mutated in colorectal and endometrial cancers , 2014, Nature Genetics.
[45] Liam O'Connor,et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. , 2014, Cancer research.
[46] Kai Ye,et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..
[47] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[48] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[49] Jean-Pierre Gillet,et al. The clinical relevance of cancer cell lines. , 2013, Journal of the National Cancer Institute.
[50] Heng Li. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.
[51] Sridhar Ramaswamy,et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..
[52] C. Ostwald,et al. Establishment, Characterization and Chemosensitivity of Three Mismatch Repair Deficient Cell Lines from Sporadic and Inherited Colorectal Carcinomas , 2012, PloS one.
[53] Sabine Tejpar,et al. A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency# , 2012, The Journal of pathology.
[54] Philippe Dessen,et al. Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer , 2012, Clinical Cancer Research.
[55] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[56] Jeremy Wazny,et al. Xenome—a tool for classifying reads from xenograft samples , 2012, Bioinform..
[57] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[58] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[59] C. Sigman,et al. Cancer biomarkers: selecting the right drug for the right patient , 2012, Nature Reviews Drug Discovery.
[60] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[61] J. Christensen,et al. MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells , 2012, Molecular Cancer Therapeutics.
[62] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[63] Víctor J Cid,et al. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. , 2011, Human molecular genetics.
[64] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[65] C. Isella,et al. Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations , 2011, Clinical Cancer Research.
[66] Derek Y. Chiang,et al. MapSplice: Accurate mapping of RNA-seq reads for splice junction discovery , 2010, Nucleic acids research.
[67] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[68] D. Zecchin,et al. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses , 2008, Proceedings of the National Academy of Sciences.
[69] A. Joe,et al. Oncogene addiction. , 2008, Cancer research.
[70] B. Dutrillaux,et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. , 2007, Cancer research.
[71] Limin Fu,et al. FLAME, a novel fuzzy clustering method for the analysis of DNA microarray data , 2007, BMC Bioinformatics.
[72] M. Gaub,et al. Primary tumour genetic alterations and intra‐tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability , 2006, The Journal of pathology.
[73] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[74] S Matsuno,et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. , 2000, Cancer research.
[75] K. Kinzler,et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.